Study identifies six drugs that can be repurposed for treatment of toxoplasmosis
Peer-Reviewed Publication
Updates every hour. Last Updated: 1-May-2025 11:08 ET (1-May-2025 15:08 GMT/UTC)
Brazilian researchers screened 160 compounds known to be effective against SARS-CoV-2 and identified those that also act against the protozoan parasite Toxoplasma gondii. The most promising will be tested in humans for treatment of the chronic form of the disease.
The study was conducted by researchers at the University of São Paulo, highlighting the importance of identify and isolating infected patients on admission to the emergency room. The findings also showed that containment may be impaired if patients stay more than two days in the ER.
A joint study by researchers from the D’Or Institute for Research and Education (IDOR), the Hospital Sírio Libanês, the Instituto do Coração (InCor), the Instituto do Câncer do Estado de São Paulo, both from the Hospital das Clínicas of the University of São Paulo Medical School and the Centro Paulista de Oncologia - Oncoclínicas, analyzed the relationship between sympathetic neural overload and exercise capacity in patients with heart failure with reduced ejection fraction (HFrEF) related to anthracycline chemotherapy. The study was published in the American Journal of Physiology-Heart and Circulatory Physiology.
A newly described coccolithophore species, Calciopappus curvus was recently found in 2020 in the Sargasso Sea near Bermuda by scientists affiliated with the Bermuda Institute of Ocean Sciences. This newly named species has also been observed prior to its discovery off Bermuda in water samples from far-flung locations as the North Atlantic to tropical and subtropical regions of the Mediterranean, the Atlantic, Indian, and Pacific Ocean. Formally named Calciopappus curvus, is described in a new paper published in the October edition of the journal Protist.